Fms-like tyrosine kinase receptor-3

Cat.No.	Product Name	Added

S1526	AC220 (Quizartinib)	Oct 2010
AC220 (Quizartinib) is a uniquely potent and selective FLT3 inhibitor with IC50 of 0.56 ± 0.3 nM and >10 mM for MC4-11 and A375, respectively.

S1134	AT9283	Dec 2009
AT9283 is a small molecule a multi-targeted c-ABL, JAK2, Aurora A and B inhibitor with of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl(T3151), Jak2 and Jak3, aurora A and B, respectively.

S1018	Dovitinib (TKI258)	Apr 2009
Dovitinib (TKI258) is a highly potent, novel multitargeted growth factor receptor kinase inhibitor with IC50 of 1, 2, 5, 10, 8, 27, 36 nM for FLT3, c-KIT, FGFR, VEGFR1/2/3, PDGFRß and CSF-1R, respectively.

S2158	KW 2449	Jan 2011
KW-2449 is a multi-kinase inhibitor of FLT3(IC50 at 6.6pM), ABL(IC50 at 14pM), ABL-T315I and Aurora kinase.

S1003	Linifanib (ABT-869)	Apr 2009
Linifanib (ABT-869) is a structurally novel, potent RTK and VEGF and PDGF receptor families inhibitor to human endothelial cells, PDGFR-β, KDR, and CSF-1R, with IC50 of 0.2, 2, 4, and 7 nM, respectively.

S1490	Ponatinib (AP24534)	Sep 2010
Ponatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor with IC50 of 0.37, 2, 1.5, 2.2, 1.1, 1and 0.24 nM for native pan-BCR-ABL, mutated form, VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosphorylation and LYN.

S1043	Tandutinib (MLN518)	Apr 2009
Tandutinib (MLN518) is a FLT3 inhibitor. In cell-based assays tandutinib inhibited FLT3 ,PDGFR, and KIT with IC50 values of 95-122 ng/mL.

S2692	TG101209	Oct 2011
TG101209 is a potent and small molecule JAK2-selective kinase inhibitor with IC50 of 6, 25, 17 and 169 nM for JAK2, FLT3, RET and JAK3, respectively.

S1119	XL184 (Cabozantinib)	Sep 2009
XL184 (Cabozantinib) is a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively.